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Conclusions: This study provides a comprehensive assessment of a
wide range of potential patient and surgical predictors associated with
outcomes of THR and the results will be useful to inform decision
making. A strength of this study is the large sample, repeated measures
of outcome over 5-years, and comprehensive internal validation
of prognostic models using multiple imputation and bootstrapping
methods. Although we identiﬁed a number of signiﬁcant predictors of
outcome, most of the difference in outcomes were predicted by the
baseline OHS, with little effect of other patient and surgical factors.
These patient groups still receiving substantial beneﬁt from surgery, for
example both obese and non obese groups receive great improvement,
even though there are small differences in pain/function at outcome
(Figure 2). Better measures of existing predictive variables, and other
factors, need to be identiﬁed that explain a greater proportion of the
variability in outcome to support patients and clinicians in making a
decision about surgery.
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OUTCOMES FOLLOWING TOTAL KNEE REPLACEMENT SURGERY FOR
OA: THERE IS MORE THAN JUST THE KNEE TO CONSIDER
A.V. Perruccio1, J.D. Power1, E.M. Badley1, R. Gandhi2, N.N. Mahomed2,
A.M. Davis1. 1Toronto Western Res. Inst.; Univ. of Toronto, Toronto, ON,
Canada; 2Toronto Western Hosp.; Univ. of Toronto, Toronto, ON, Canada
Purpose: The most common outcomes examined in total knee
replacement (TKR) for osteoarthritis (OA) are pain and physical function.
And, TKR is an effective treatment for relieving pain and improving
function. While people with OA often have multiple symptomatic joints,
however, the impact of this on these TKR outcomes has received little
attention. This work evaluated whether the occurrence and location
of symptomatic joints predicted change in WOMAC pain and physical
function following TKR, and whether multiple joint involvement was
associated with the likelihood of achieving a minimally clinically
important difference (MCID) in pain and function. The inﬂuence of
multiple joint involvement on a number of additional TKR outcomes
was also examined.
Methods: Participants (n = 494) completed pain and physical function
measures (WOMAC, KOOS (which subsumes the WOMAC) and CPG),
sports/recreation (KOOS), fatigue (POMS), and anxiety and depression
(HADS) pre surgery and at 12 months post surgery. Comorbidity was
based on number of conditions. Symptomatic joints were indicated on a
homunculus based on pain or discomfort on most days of the previous
month. Symptomatic joints were separately considered as a summative
count and by joint site as an independent predictor of change in WOMAC
pain and function by way of regression analyses, adjusting for covariates:
age, sex, BMI, comorbidity, and baseline status for each measure. Logistic
regression analyses examined the effect of joint involvement (count and
site) on achieving an MCID on WOMAC pain and function, adjusted for
covariates. Finally, the effect of joint involvement on change in the other
outcomes was also examined.
Results: Ages ranged from 35–88 years (mean = 65) with 65% female.
15% of the sample was symptomatic in only their surgical joint; 46%
reported ≥5 symptomatic joints. Mean change scores across all measures
varied depending on whether speciﬁc joint sites were indicated. The least
amount of change was observed among participants reporting feet/ankle
and neck as problematic joints. This was conﬁrmed in regression
analyses. Adjusting for covariates and all joint sites, individuals reporting
neck problems had less change across all measures (p range: 0.0020–
0.0493), except KOOS sport/rec. Individuals reporting feet/ankles also had
less change across measures (p range: 0.0002–0.0136), except fatigue and
anxiety. For fatigue, back problems were also associated with less change.
Although joint count was a signiﬁcant predictor across all measures,
except KOOS sport/rec, the magnitude of the coefﬁcients were highly
attenuated in comparison to some speciﬁc joint sites, particularly neck
and feet/ankle. Adjusted for covariates, baseline status, and all joint sites,
logistic regression results indicated that individuals reporting feet/ankle
had reduced odds of achieving a MCID for WOMAC pain (OR: 0.32, 95%CI:
0.185, 0.544) and function (OR: 0.53, 95%CI: 0.303, 0.940). Additionally,
individuals reporting neck problems had reduced odds of achieving a
MCID for WOMAC physical function (OR: 0.37, 95%CI: 0.183, 0.726).
Conclusions: While TKR is an effective treatment, these study results
suggest that TKR outcomes may be further improved if a more holistic
approach to OA management were adopted. While systemic effects may
be operational in OA, the contribution of speciﬁc joints is unclear.
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Purpose: Several studies have explored the socioeconomic burden of
osteoarthritis (OA). However, although treatment guidelines uniformly
recommend a multidisciplinary approach to OA pain management, a
thorough evaluation of the use and costs of alternative treatments for
the management of OA is lacking. The objective of this study was to
evaluate the use and direct medical costs of pharmacologic and non-
pharmacologic (alternative) treatments for patients with OA in usual
care settings in the United States.
Methods: Using the LifeLink™ Health Plan Claims Database, all patients
at least 18 years of age, with one or more healthcare encounters
with an associated diagnosis of OA (ICD-9-CM code 715.XX) during
each of calendar years (CY) 2007 and 2008 were identiﬁed. OA
patients who were continuously enrolled during CY2008 and received
a prescription for non-selective nonsteroidal anti-inﬂammatory drugs
(NS-NSAIDs), Cyclooxygenase-2 inhibitors (Cox-2s), acetaminophen,
tramadol, weak opioids and strong opioids any time during the year
were then selected. Patterns of pain-related pharmacotherapy, alternative
treatments and direct medical costs associated with these therapies,
as well as total healthcare costs (ofﬁce visits, emergency room visits,
hospitalizations, other outpatient services) were examined among this
group of patients during CY2008. Additionally, adherence to select pain-
related medications was also evaluated using a Medication Possession
Ratio (MPR).
Results: A total of 64,085 OA patients were included in the
analysis (average age: 56.4±9.3 years; 63% female). Patients had
multiple comorbidities (hypertension, 56%; hyperlipidemia, 52%;
gastroesophageal reﬂux disease, 19%; low back pain, 36%; back and
neck pain with neuropathic involvement, 17%) and a substantial pain
and adjuvant medication burden. Opioids were the most commonly
prescribed pain-related medication (72%), followed by NS-NSAIDs (55%);
32% of patients received antidepressants, 21% received benzodiazepines,
and 15% received sedative hypnotics during CY2008. Nearly 1 out of
4 (23%) patients used assistive devices, 20% had physical therapy, 11% saw
a chiropractor and 14% received TENS during CY2008. Use of treatments
like acupuncture, hydrotherapy, massage therapy, and biofeedback was
less than 2%. Less than 30% of patients achieved an MPR in excess of
80% for any of the evaluated medication classes with the average (±SD)
MPR being the highest for Cox-2 inhibitors (55% ± 29%). Mean (SD)
total healthcare costs among these patients were $15,614 ($22,581);
pharmacologic therapies accounted for 21% of these costs, whereas
alternative treatments accounted for only 3% of the total costs.
Conclusions: Results suggest that OA patients who received pain-related
medications had a high prevalence of comorbidities, and also used
adjuvant medications commonly prescribed for pain associated sequelae
including anxiety, depression, and sleep disorders. Although, non-
pharmacologic therapies are widely recommended, we found limited
use of many of these treatments in usual care. However, the observed
low use might be partly due to the source of our data (commercial
claims), since alternative treatments might be paid out-of-pocket by
patients. Further research is needed to ascertain the extent to which
such therapies contribute to the total costs of OA management.
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A HIGH PREVALENCE AND IMPACT OF CHRONIC JOINT SYMPTOMS
IN THE YOUNGER POPULATION: IS THIS OSTEOARTHRITIS?
M. Canizares, E.M. Badley. Univ. Hlth.Networks, Toronto, ON, Canada
Purpose: Arthritis is one the most common chronic conditions affecting
15%-20% of the population. Estimates from population surveys show a
further 10%-15% of the population reporting chronic joint symptoms
(CJS). CJS have been considered as an indication of possible arthritis
with studies showing conﬂicting results. Most of these studies have
compared individuals with CJS to those with arthritis in terms of their
predictors and only a minority have considered health-related outcomes.
This study examines predictors and health outcomes for individuals with
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self-reported arthritis and those without arthritis reporting chronic or
sporadic joint symptoms compared to those who have no arthritis and
no joint symptoms.
Methods: Data from the 2008 Canadian Community Health Survey
(15+; n =66,013) were used for analyses. Respondents were asked about
arthritis as a long-term chronic health condition diagnosed by a health
professional. Participants not-reporting arthritis were asked about joint
symptoms excluding back and neck over the past 12 months. Analyses
were conducted for the following mutually exclusive groups: arthritis,
chronic joint symptoms (symptoms present on most days in the past
month), sporadic joint symptoms (other joint symptoms in the past
12 months (SJS)), and no arthritis and no joint symptoms (NJS). Log-
Poisson regression was used to determine risk factors for each of these
groups. Similar regressions, adjusting for socio-demographic, lifestyle
factors, and comorbidities were used to estimate the risks of reporting
physical inactivity, health outcomes (poor/fair overall health, poor/fair
mental health, activity limitation), and ﬁve measures of healthcare
use.
Results: 16.0% of the population reported arthritis, 10.1% reported CJS
and 11.6% reported SJS. Individuals with arthritis were older than those
with CJS or SJS. Women reported arthritis and CJS more often while men
reported SJS. Other than age, the proﬁle of risk factors for arthritis and
CJS was similar, notably obesity and overweight. After adjusting for age,
sex, SES, lifestyle factors and comorbidities, prevalence ratios showed
similar risks for physical inactivity, health outcomes and health care use
for the arthritis and CJS group, and these were higher than those for SJS
group.
Conclusions: CJS was reported by one-in-ten of the adult population. The
similarities in risk factors, other than younger age, for CJS and arthritis
suggest that the CJS group represent people in early stages of arthritis
(based on population frequency most likely osteoarthritis) who have not
yet being diagnosed. The impact that CJS has on health outcomes and
increased healthcare use was similar to that of arthritis, suggesting that
arthritis education and management interventions are likely beneﬁcial
for this group with possible unrecognized OA.
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THE mtDNA HAPLOGROUP J MODULATES THE NITRIC OXIDE
(NO) PRODUCTION AND TELOMERE LENGTH. ROLE IN
OSTEOARTHRITIS (OA)
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Purpose: (1) To measure the telomere length of chondrocytes and
peripheral blood leukocytes (PBLs) in OA patients and healthy controls,
and (2) To analyze the incidence of the mtDNA haplogroup J in both
the telomere length and the Nitric Oxide (NO) production, as indirect
approaches of oxidative stress.
Methods: The telomere length was analyzed by means of a validated
qPCR method. For the comparison of the telomere length between
OA patients and healthy controls, the DNA was obtained from both
uncultured chondrocytes and blood of the same individual in a cohort
of 39 OA patients and 20 healthy controls from Hospital Universitario
A Corun˜a. A second larger cohort of 166 healthy controls and 79 OA
patients was used to compare the telomere length of PBLs between
haplogroup J (n = 155) and non-J carriers (n = 90), as well as between
OA patients and healthy controls. The NO production was assessed in
7 carriers of the haplogroup J and 21 non-J carriers by means of the
Griess reagent in the supernatants of cultured chondrocytes. Inducible
nitric oxide synthase (iNOS) mRNA from these samples was analyzed
by qPCR. Appropriated statistical approaches were carried out using
SPSS v1.17.
Results: The telomere length in chondrocytes was assessed as the
ratio “telomere length of chondrocytes: telomere length of PBLs of the same
individual”, and was signiﬁcantly shorter in OA patients than in healthy
controls (1.72±0.41 vs 2.12±0.64; mean±sd; p = 0.028). No statistical
differences were detected between OA patients and healthy controls
when analyzed the telomere length of PBLs in the larger cohort set;
however, carriers of the haplogroup J showed a signiﬁcantly longer
telomere length of PBLs than non-J carriers, regardless of age, gender
and diagnosis (p = 0.025). The NO production for chondrocytes carrying
this haplogroup was also signiﬁcantly lower (p = 0.05), and a strong
positive correlation between NO production and iNOS expression was
also observed (correlation coefﬁcient = 0.791, p < 0.001).
Conclusions: The decreased telomere length in chondrocytes from OA
affected joints may imply a local advanced senescence that could
contribute to the pathogenesis or progression of OA. The relation of
the mtDNA haplogroup J with both lower NO production and longer
telomere length of PBLs indicates a lower oxidative stress in carriers of
the mtDNA haplogroup J, which could explain the protective effect of
this haplogroup in the OA disease.
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SYNTHASE (INOS) IS RESPONSIBLE OF GENE INDUCTION IN HUMAN
ARTICULAR CHONDROCYTES
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Osteoarthritis (OA) is a complex disease of the joint, associated
with cartilage degradation by matrix proteases (aggrecanases and
collagenases). Nitric oxide (NO), the product of inducible nitric oxide
synthase (iNOS), not only suppresses the synthesis of cartilage matrix,
but also increases expression of proteases in OA; however, normal
chondrocytes do not produce NO. Although iNOS is readily inducible
in almost all rodent cell types in culture, in contrast, normal human
cells are recalcitrant to induction with cytokines due to epigenetic
silencing by DNA methylation. Unlike the murine iNOS promoter, the
ﬁrst 1.0 kb of the human iNOS gene 5′ ﬂanking region is not sufﬁcient for
iNOS induction. Instead, inducible NF-kB elements upstream −4.7 kb are
required for cytokine activation of the promoter. However, it is not known
whether the activation of iNOS in OA chondrocytes can be attributed to
epigenetic “unsilencing” with implications for therapeutic intervention
in OA.
Objective: To examine and correlate mRNA expression of iNOS with
the DNA methylation status of speciﬁc CpG sites in the iNOS promoter
and NF-kB enhancer elements regions, and to examine if the increased
expression of iNOS in OA chondrocytes is attributable to loss of DNA
methylation.
Methods: Control chondrocytes were obtained from fracture neck of
femur (#NOF) patients; these patients typically suffer from osteoporosis,
which does not affect the cartilage. #NOF patients are widely used as
a suitable non-OA control. OA chondrocytes were isolated from the
femoral heads of patients undergoing hip replacement surgery due
to OA. Genomic DNA and total RNA were extracted simultaneously.
Expression of iNOS was quantiﬁed by qRT-PCR and the DNA methylation
status of the iNOS promoter and enhancer regions was determined
by bisulﬁte modiﬁcation, followed either by cloning and sequencing
or pyrosequencer analysis to quantify percentage methylation. CpG
methylation on activities of both iNOS enhancer and promoter was
determined using reporter assay with CpG-free luciferase vector and
a CpG methyltransferase (M.SssI). On the other hand, co-transfections
with NF-kB subunits (p50, p65 and p50/p65) were carried out to analyse
the effect of this transcription factor on iNOS activity.
Results: OA samples showed a 13-fold increase in iNOS expression
compared to #NOF samples (n = 14, P< 0.05). The iNOS promoter has
only 7 CpG sites in over 1000bp, 6 of which were highly methylated
in both controls and OA and the CpG site at −289 was un-methylated
in both groups; the sites in the coding region (+13, +33 and +38), were
largely unmethylated in #NOF and OA patients. Three NF-kB enhancer
elements regions were analyzed by pyrosequencing, the enhancer regions
at −5.2 kb and −5.4 kb were found to be totally unmethylated in all
samples (<10%); however, the enhancer region at −5.8 was signiﬁcantly
de-methylated in OA samples (n = 12, P < 0.05) compared with #NOF
samples, with an approximate 10% loss of methylation. Transcriptional
activation of iNOS was possible after co-transfection of the −5.8 kb
enhancer element with p65 (45-fold increase, n = 5, P< 0.05) or p50/p65
NF-kB subunits (15-fold increase, n = 5, P< 0.05). Critically, methylation
treatment of the enhancer element was associated with a 25-fold
decrease in iNOS activity in reporter assay.
